ReviewJournal of clinical medicine2020
Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective.
Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Pharmacokinetics, Bioequivalence and Safety Evaluation of Two Ticagrelor Tablets Under Fasting and Fed Conditions in Healthy Chinese Subjects.Drug design, development and therapy · 2021Trial
- Gastrointestinal Bleeding Is Associated with Worse In-Hospital Outcomes in Patients with ST-Segment Elevation Myocardial Infarction: An Analysis of the National Inpatient Sample.Journal of clinical medicine · 2026Article
- Beliefs of medicine questionnaire: Translation, validation, and adaptation for post-acute coronary syndrome patients in the south of Sulawesi population, Indonesia.Exploratory research in clinical and social pharmacy · 2026Article
- Pharmacological Evaluation of Ticagrelor and Aspirin Versus Clopidogrel and Aspirin Pretreatment on Infarct Artery Flow in Patients with Acute STEMI.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Sex-Related Differences in On-Treatment Platelet Reactivity in Patients with Acute Coronary Syndrome.Biomedicines · 2025Article
- Comparative Safety of Anticoagulant, Antiplatelet and the Combination of Both for Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis.Biomedicines · 2025Review
- Review
- Dual antiplatelet therapy in GI-bleed patients with extensive coronary artery disease history: a systematic review.Annals of medicine and surgery (2012) · 2025Review
- Risk Factors for Upper Gastrointestinal Bleeding in Patients Undergoing Percutaneous Coronary Intervention on Dual Antiplatelet Therapy with Assessment of Anti-Ulcer Medication Effects.Acta Cardiologica Sinica · 2025Article
- Elderly patients are hyperresponsive to potent P2Y12 inhibitors.Research and practice in thrombosis and haemostasis · 2025Article
- Risk Factors for Gastrointestinal Bleeding in Patients With Acute Myocardial Infarction: Multicenter Retrospective Cohort Study.Journal of medical Internet research · 2025Article
- Article
- Successful treatment of acute coronary syndrome complicated with massive gastrointestinal bleeding: A case report.Heliyon · 2024Article
- Impact of prior aspirin use on left ventricular function in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: An echocardiographic evaluation.Journal of cardiovascular and thoracic research · 2024Article
- Growth Differentiation Factor 15 Is Associated with Platelet Reactivity in Patients with Acute Coronary Syndrome.Journal of clinical medicine · 2023Article
- Clinical characteristics and risk factors of in-hospital gastrointestinal bleeding in patients with acute myocardial infarction.Frontiers in cardiovascular medicine · 2022Article
- A retrospective observational study of the use of gastroprotection for patients on dual antiplatelet therapy.The British journal of cardiology · 2022Article
- Bilateral multifocal muscular hemorrhage in the triceps surae during antiplatelet therapy: a case report.The Journal of international medical research · 2021Article
- Dual antiplatelet therapy is under-prescribed in patients with surgically treated acute myocardial infarction.Interactive cardiovascular and thoracic surgery · 2021Observational
- Recent Advances of Cell Membrane Coated Nanoparticles in Treating Cardiovascular Disorders.Molecules (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inhibition of platelet function by means of dual antiplatelet therapy (DAPT) is the cornerstone of treatment of acute coronary syndrome (ACS). While preventing ischemic recurrences, inhibition of platelet function is clearly associated with an increased bleeding risk, a feared complication that may lead to significant morbidity and mortality. Since bleeding risk management is intrinsically associated with therapeutic adjustments undertaken during the whole clinical history of patients with acute coronary syndrome, single decisions taken from the very first day to years of follow-up might be decisive. This review aims at providing a clinically oriented, patient-tailored approach in reducing the risk and manage bleeding complications in ACS patients treated with DAPT. The steps in clinical decision making from the day of ACS to follow-up are analyzed. New treatment strategies to enhance the safety of DAPT are also described.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.